Brief: Sequana Medical FY EBIT Loss Widens To 14 Million Euros

Sequana Medical NV

19/03/2020 06:19

March 19 (Reuters) - Sequana Medical NV  SEQUA.BR :
    * FY EPS LOSS 1.22 EUR VERSUS 1.40 EUR LOSS YEAR AGO
    * FY EBIT LOSS EUR 13.9 MILLION VERSUS LOSS EUR 13.1 MILLION
YEAR
AGO
    * EXPECTS DELAYS TO EXECUTION OF CLINICAL STUDIES AND IMPACT
SALES
    * FY NET LOSS EUR 15.0 MILLION VERSUS LOSS EUR 14.0 MILLION
YEAR
AGO
    * GLOBAL HEALTH CRISIS, SPECIFICALLY RESTRICTIONS ON
NON-ESSENTIAL
MEDICAL PROCEDURES AND HOSPITAL VISITS, MAY IMPACT SALES
    * 2019 NET CASH OUTFLOW FROM OPERATING ACTIVITIES WAS EUR
18.48
MILLION COMPARED TO NET CASH OUTFLOW OF EUR 9.88 MILLION IN 2018
    * NET DEBT AT 31 DEC 2019 DECREASED BY €15.70 MILLION,
RESULTING
IN POSITIVE NET CASH POSITION OF €2.36 MILLION
    * 2019 TOTAL LIQUIDITY POSITION OF EUR 5.59 MILLION (2018:
EUR
1.32 MILLION)
    * FY REVENUE EUR 971 MILLION VERSUS EUR 1.03 BILLION YEAR
AGO
    * RESULTS FROM THE ALFAPUMP DSR RED DESERT STUDY INITIALLY
EXPECTED IN Q2 AND Q3 2020 MAY BE DELAYED

Source text for Eikon:  ID:nGNE39695M 
Further company coverage:  SEQUA.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))